mometasone furoate; olopatadine hydrochloride · Glenmark Speclt · NDA 211746

Ryaltris

Earliest generic entry, as listed
21 Nov 2044

Blocked by patent: US 12653833.

Listed patents · 17 unexpired

PatentClaimsExpires
US 12653833drug product, use U-4564 · sets the listed date21 Nov 2044
US 12303635drug substance, drug product8 Apr 2039
US 11679210drug product3 Sep 2038
US 10016443use U-32974 Sep 2034
US 10376526drug product4 Sep 2034
US 10517880drug product, use U-32974 Sep 2034
US 10548907use U-32974 Sep 2034
US 10561672drug product4 Sep 2034
US 10646500use U-32974 Sep 2034
US 10758550use U-32964 Sep 2034
US 10765686use U-32954 Sep 2034
US 11400101use U-32974 Sep 2034
US 12064442use U-32974 Sep 2034
US 9078923drug product, use U-32974 Sep 2034
US 9370483drug product4 Sep 2034
US 9750754drug product, use U-32974 Sep 2034
US 9937189drug product4 Sep 2034

Exclusivities · 1 unexpired

NPPnew patient population7 Jul 2029

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
211746 · 001 · RLDspray, metered, nasal0.025MG/SPRAY;0.665MG/SPRAY21 Nov 2044